Luminal A and Luminal B subtypes in patients with breast cancer 65 years of age and older.

Robert Königsberg(Kaiser-Franz-Josef-Spital), Christian Dittrich(Leibniz Institute for Agricultural Engineering and Bioeconomy), Tatjana Klement(Medical University of Vienna), Nicole Hammerschmid(Medical University of Vienna), Georg Pfeiler(Medical University of Vienna)

Journal of Clinical Oncology

May 20, 2013

10.1200/jco.2013.31.15_suppl.549

Cited by 1

Related Papers

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization

|Blood|2000|322

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

|The Lancet Oncology|2021|255

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients

|Acta Oncologica|2011|239

Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

|Journal of Clinical Oncology|2008|226

Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial

|Journal of Clinical Oncology|2011|222